ALNA stock drops 99% since IPO, trades at $0.075 on NASDAQ

Allena Pharmaceuticals, Inc. (ALNA) trades at just $0.075 per share on NASDAQ, down 99.2% since its 2017 IPO. The biopharmaceutical company, headquartered in Newton, Massachusetts, focuses on oral enzyme therapeutics for rare kidney and metabolic disorders. ALNA stock has lost 81.4% over the past year alone, reflecting mounting losses and cash burn. With 252 million shares trading today and a current grade of C+, investors should understand the company’s financial position before considering any positions. The stock’s dramatic decline mirrors broader challenges in early-stage biotech development.

ALNA Stock Price Action and Trading Volume

ALNA stock closed at $0.075 per share, up 3.16% from the previous close of $0.0727. The stock traded between a low of $0.06 and a high of $0.1459 during the session, showing significant intraday volatility. Trading volume reached 252.3 million shares, indicating active participation despite the stock’s distressed valuation.

The price movement reflects ongoing market skepticism about the company’s pipeline. ALNA stock has declined 38.1% over six months and 96.8% over three years. These losses far exceed typical biotech volatility, suggesting fundamental concerns about the company’s ability to advance its lead candidate, ALLN-346, through clinical development.

Financial Metrics and Valuation Concerns

Allena Pharmaceuticals shows deeply negative financial metrics across the board. The company reported a net loss of $1.03 per share and negative operating cash flow of $1.41 per share. Book value stands at just $0.58 per share, while ALNA stock trades at only 0.13 times book value, suggesting severe market distrust.

The company holds $0.92 per share in cash, providing some runway for operations. However, with negative earnings and no revenue generation, cash burn remains a critical concern. The current ratio of 2.1 indicates adequate short-term liquidity, but this provides limited comfort given the company’s unprofitable operations and uncertain path to commercialization.

Lead Product and Business Model

ALLN-346 represents Allena’s primary focus, a novel urate-degrading enzyme targeting hyperuricemia and gout in advanced chronic kidney disease patients. This rare disease indication addresses an underserved market with limited treatment options. The company employs 120 full-time staff to advance this pipeline.

As a pre-revenue biopharmaceutical company, Allena depends entirely on clinical trial success and eventual regulatory approval. The company’s business model requires significant capital investment with no near-term revenue prospects. Track ALNA on Meyka for real-time updates on clinical trial announcements and regulatory developments that could impact the stock’s trajectory.

Market Sentiment and Investment Grade

Meyka AI rates ALNA with a grade of C+, suggesting a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score of 58.97 reflects significant concerns about the company’s financial health and development timeline.

The biotechnology sector remains volatile, and early-stage companies face heightened scrutiny. ALNA stock’s massive decline reflects both sector headwinds and company-specific challenges. These grades are not guaranteed and we are not financial advisors. Investors should conduct thorough due diligence before making any investment decisions regarding distressed biotech stocks.

Final Thoughts

ALNA stock trades at $0.075 per share, representing a 99.2% decline since the company’s 2017 IPO. Allena Pharmaceuticals faces significant financial headwinds, including negative earnings, zero revenue, and substantial cash burn. The company’s sole focus on ALLN-346 development creates binary risk for shareholders. While the rare disease indication offers potential upside if clinical trials succeed, the path to profitability remains uncertain and distant. The C+ grade reflects these fundamental challenges. Investors considering ALNA stock should recognize the high-risk nature of pre-revenue biotech investments and ensure any position aligns with their risk tolerance and investment timeline.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.